The present invention relates to a novel bacteriophage CJ24 (KCCM11462P) and a composition comprising the same as an active component. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by avian pathogenic E. coli of birds by using the bacteriophage CJ24 (KCCM11462P) or the composition.

The present invention relates to the field of probiotic adjuvantization of anticancer treatments. In particular, the present invention concerns immunogenic sequences from a prophage present in bacteria identified as efficient adjuvants of cancer treatments. The invention provides bacterial compositions expressing immunogenic sequences from this prophage, immunogenic compositions comprising such sequences and methods using sequences from this prophage, for increasing the anticancer armamentarium.

Provided herein are antibacterial compositions and methods of making and using the compositions.

Provided herein are antibacterial compositions and methods of making and using the compositions.

The present invention relates to a novel bacteriophage CJ24 (KCCM11462P) and a composition comprising the same as an active component. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by avian pathogenic E. coli of birds by using the bacteriophage CJ24 (KCCM11462P) or the composition.

The invention relates to a method of preventing or treating pathogenic bacterial infectious diseases by providing a pharmaceutical composition comprising a LysSAP26 protein, wherein the LysSAP26 protein is a recombinant protein composed of an amino acid sequence derived from the bacteriophage genome and has the amino acid sequence set forth in SEQ ID NO: 1 as an active ingredient, and administering the pharmaceutical composition to a subject.

Provided herein are antibacterial compositions and methods of making and using the compositions.